Certara was formed through the integration of Tripos, Pharsight, Simcyp, and Synchrogenix, creating a company that offers a broad spectrum of scientific consulting services and software products from early drug discovery through clinical drug development, with special focus on model based approaches to drug development.
Certara is the only company that provides expertise spanning drug discovery and development – with modeling, analysis, and simulation methods that include molecular modeling, PK/PD modeling and simulation, PBPK modeling and simulation, and regulatory writing and submission services. With these capabilities, Certara is uniquely able to help our customers accelerate decision making, and enable the cross-disciplinary approaches necessary for translational science.
Global scientific team applies quantitative analysis and predictive models of diseases, drugs and clinical trials to support strategic decisions and new drug submissions. Learn More